Allogene Therapeutics, Inc.
ALLO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ALLO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ALLO
Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic CAR T cell therapies for cancer and autoimmune disease, with its lead candidate cema-cel in a pivotal Phase 2 trial for first-line MRD-guided consolidation in large B-cell lymphoma.
Key risk: Clinical and regulatory uncertainty
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 8 clinical trials for Allogene Therapeutics, Inc..
Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic CAR T cell therapies for cancer and autoimmune disease, with its lead candidate cema-cel in a pivotal Phase 2 trial for first-line MRD-guided consolidation in large B-cell lymphoma.
- Allogene is a clinical-stage biotechnology company pioneering allogeneic CAR T cell products for cancer and autoimmune disease [sec · filed 2026-04-30].
- The company advanced its pivotal Phase 2 ALPHA3 trial evaluating cemacabtagene ansegedleucel (cema-cel) as a first-line MRD-guided consolidation therapy [sec · filed 2026-04-30].
- As of June 30, 2026, Allogene reported cash and equivalents of $48.9M, total revenue of $4.6M, and a net loss of -$42.7M [sec].
- In May 2025, Allogene initiated a workforce reduction of approximately 28% [sec_mda · as of 2026-03-12].
- The company has an Amended and Restated Strategic Collaboration Agreement with Foresight Diagnostics (acquired by Natera) to support MRD assay development for cema-cel in the EU, UK, Canada, and Australia [sec_mda · as of 2026-03-12].
What works
- Allogene's lead candidate cema-cel is in a pivotal Phase 2 trial (ALPHA3) for first-line MRD-guided consolidation, a potentially earlier and larger market opportunity in large B-cell lymphoma [sec · filed 2026-04-30].
- The company has a strategic collaboration with Foresight Diagnostics (Natera) to expand MRD assay development into the EU, UK, Canada, and Australia, supporting cema-cel's clinical development [sec_mda · as of 2026-03-12].
- Allogene has an option to expand its licensed territory to include China and Japan upon demonstrating sufficient resources, which could broaden its market reach [sec_mda · as of 2026-03-12].
What to weigh
- Allogene reported a net loss of -$42.7M for the quarter ended June 30, 2026, with accumulated deficits and ongoing operating losses typical of a development-stage biotech [sec].
- The company's cash and equivalents of $48.9M as of June 30, 2026, may require additional financing to support ongoing clinical trials and operations [sec].
- Allogene's product candidates are based on novel technologies, making it difficult to predict development timelines and regulatory approval [sec · filed 2025-08-01].
- In May 2025, Allogene implemented a workforce reduction of approximately 28%, indicating cost-cutting measures amid financial pressures [sec_mda · as of 2026-03-12].
From the filings
Quoted directly from source documents.
Allogene is a clinical-stage biotechnology company pioneering allogeneic CAR T cell products for cancer and autoimmune disease.
“We are a clinical-stage biotechnology company pioneering the development of allogeneic CAR T cell products for cancer and autoimmune disease.”
SEC filings · April 30, 2026
The company advanced its pivotal Phase 2 ALPHA3 trial evaluating cema-cel as a first-line MRD-guided consolidation therapy.
“Advanced the pivotal Phase 2 ALPHA3 trial evaluating cemacabtagene ansegedleucel ("cema-cel") as a first-line (1L) MRD-guided conso”
SEC filings · April 30, 2026
Allogene initiated a workforce reduction of approximately 28% in May 2025.
“In May 2025, we initiated a workforce reduction of approximately 28% of ou”
SEC MD&A · March 12, 2026
The company has an option to expand its licensed territory to include China and Japan.
“ier Amendment also grants us an option to further expand the licensed territory to include China and Japan upon the objective showing of sufficient resources to develop licensed products in those countries”
SEC MD&A · March 12, 2026
Risks & what to watch (4)›
Key risks
- Clinical and regulatory uncertainty — Allogene's product candidates are based on novel technologies, making it difficult to predict development timelines and regulatory approval [sec · filed 2025-08-01].
- Limited cash runway — Cash and equivalents of $48.9M as of June 30, 2026, may require additional financing to support ongoing trials and operations [sec].
- Dependence on single lead candidate — The company's near-term prospects are heavily reliant on the success of cema-cel in the ALPHA3 trial [sec · filed 2026-04-30].
- Workforce reduction impact — A 28% workforce reduction in May 2025 may affect operational capacity and morale [sec_mda · as of 2026-03-12].
What to watch
- Enrollment and data readouts from the pivotal Phase 2 ALPHA3 trial of cema-cel [sec · filed 2026-04-30].
- Cash burn rate and any additional financing activities, including ATM offerings [sec_mda · as of 2026-03-12].
- Progress of the collaboration with Foresight Diagnostics/Natera for MRD assay development in new territories [sec_mda · as of 2026-03-12].
- Any updates on the option to expand licensed territory to China and Japan [sec_mda · as of 2026-03-12].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Allogene Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Allogene Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
30.8 months
D/E 0.26 · 0% dilution
Lead: Phase 3
5 candidates
No upcoming catalysts tracked
0 buys · 4 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
206
Total value held
$360.1M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 19,091,095 | $46.6M |
| vanguard capital management llc | 13,842,700 | $33.8M |
| state street corp | 8,660,306 | $21.1M |
| primecap management co/ca/ | 8,379,840 | $20.4M |
| woodline partners lp | 7,002,156 | $17.1M |
| citadel advisors llc | 6,887,120 | $16.8M |
| two sigma investments, lp | 5,375,456 | $13.1M |
| geode capital management, llc | 4,124,178 | $10.1M |
| frazier life sciences management, l.p. | 3,796,668 | $9.3M |
| patient square capital lp | 3,450,000 | $8.4M |
Showing top 10 of 206 institutional holders of Allogene Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 11.8%
- Days to cover
- 2.4
- Shares short
- 36,856,587
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ALLO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Allogene Therapeutics, Inc.?
Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic CAR T cell therapies for cancer and autoimmune disease, with its lead candidate cema-cel in a pivotal Phase 2 trial for first-line MRD-guided consolidation in large B-cell lymphoma.
What is Allogene Therapeutics, Inc.'s lead drug candidate?
Allogene Therapeutics, Inc.'s most advanced tracked candidate is ALLO-316 (Phase 2) for Advanced/Metastatic Clear Cell Renal Cell Carcinoma.
Who is the CEO of Allogene Therapeutics, Inc.?
Dr. Zachary J. Roberts M.D., Ph.D. is the chief executive officer of Allogene Therapeutics, Inc. (ALLO).
Where is Allogene Therapeutics, Inc. headquartered?
Allogene Therapeutics, Inc. (ALLO) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does Allogene Therapeutics, Inc. focus on?
Allogene Therapeutics, Inc. develops therapies across Oncology, Gene Therapy, Immunology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.